Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (501-510 of 584) with videos related to

Pageof 59
Sort By:
Blood|March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesFrancis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
Leukemia|June 1, 2022
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trialTim H Brümmendorf, Jorge E Cortes, Dragana Milojkovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Cancer|August 2, 2016
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Blood Advances|February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized TrialShai Shimony, H Moses Murdock, Julia H Keating, et al.
Cancer|August 11, 2016
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2024
Project Confirm: Accelerated Drug Approvals for CML-ResponseKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
American Journal of Hematology|April 9, 2014
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-upCarlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, et al.
American Journal of Hematology|December 23, 2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitorNicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
Pageof 59

Showing results (501-510 of 584) with videos related to

Sort By:
Pageof 59
Blood|March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesFrancis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
Leukemia|June 1, 2022
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trialTim H Brümmendorf, Jorge E Cortes, Dragana Milojkovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Cancer|August 2, 2016
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Blood Advances|February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized TrialShai Shimony, H Moses Murdock, Julia H Keating, et al.
Cancer|August 11, 2016
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2024
Project Confirm: Accelerated Drug Approvals for CML-ResponseKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
American Journal of Hematology|April 9, 2014
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-upCarlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, et al.
American Journal of Hematology|December 23, 2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitorNicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
Pageof 59